Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Free Cash Flow (2017 - 2025)

Historic Free Cash Flow for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to -$9.0 million.

  • Cue Biopharma's Free Cash Flow fell 1990.43% to -$9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.8 million, marking a year-over-year increase of 2219.29%. This contributed to the annual value of -$36.4 million for FY2024, which is 892.37% up from last year.
  • Per Cue Biopharma's latest filing, its Free Cash Flow stood at -$9.0 million for Q3 2025, which was down 1990.43% from -$3.4 million recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Free Cash Flow ranged from a high of -$3.4 million in Q2 2025 and a low of -$12.9 million during Q2 2022
  • Moreover, its 5-year median value for Free Cash Flow was -$10.0 million (2024), whereas its average is -$9.4 million.
  • Over the last 5 years, Cue Biopharma's Free Cash Flow had its largest YoY gain of 9179.16% in 2021, and its largest YoY loss of 10749.93% in 2021.
  • Over the past 5 years, Cue Biopharma's Free Cash Flow (Quarter) stood at -$10.6 million in 2021, then grew by 1.22% to -$10.5 million in 2022, then fell by 4.21% to -$11.0 million in 2023, then increased by 17.59% to -$9.0 million in 2024, then rose by 0.07% to -$9.0 million in 2025.
  • Its Free Cash Flow was -$9.0 million in Q3 2025, compared to -$3.4 million in Q2 2025 and -$8.3 million in Q1 2025.